GGrantIndex
Sort

82,697 grants matching vaccine development

Analysis of Host-Pathogen Interactions

$849,013
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Biomedical Studies and Atomic Force Microscopy

$848,997
Albert J Jin · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2010 · EB

KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection

$848,928
Javier Gordon Ogembo · Beckman Research Institute/City Of Hope · R01 · FY2024 · AI

Hepatitis C: Studies of Immunity and Pathogenesis

$848,905
Rockefeller University · U19 · FY2005 · AI

Novel Targets for Vaccine Therapy

$848,816
Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA

Broad spectrum inhibitors of paramyxovirus envelope proteins

$848,745
Anne Moscona · Columbia University Health Sciences · R01 · FY2023 · AI

Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccine

$848,727
Joana Carneiro Da Silva · University Of Maryland Baltimore · R01 · FY2019 · AI

KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection

$848,656
Javier Gordon Ogembo · Beckman Research Institute/City Of Hope · R01 · FY2025 · AI

Malaria Vaccine: Pfs230

$848,566
Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors

$848,532
Laurent Karl Verkoczy · San Diego Biomedical Research Institute · R01 · FY2019 · AI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens

$848,466
Shane P Crotty · La Jolla Institute For Immunology · R01 · FY2017 · AI

Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae

$848,444
Edward Hook · University Of Alabama At Birmingham · N01 · FY2024 · AI

Recombinant Vaccines for Prevention of AIDS and Other Diseases

$848,411
Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Signal Transduction Events and the Regulation of Cell Growth

$848,376
Jane Neckers · Division Of Clinical Sciences - Nci · ZIC · FY2017 · CA

Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection

$848,374
Sallie R. Permar · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AI

University of Miami Pediatric Perinatal HIV/AIDS Clinical Trails Unit

$848,314
Gwendolyn B. Scott · University Of Miami School Of Medicine · U01 · FY2009 · AI

Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia

$848,308
Jodi K Craigo · Cytoagents, Inc. · R44 · FY2020 · AI

Mapping spatiotemporal dynamics during enterovirus infection across cells and tissues

$848,303
Raul Andino · University Of California, San Francisco · R01 · FY2024 · AI

Mapping spatiotemporal dynamics during enterovirus infection across cells and tissues

$848,303
Raul Andino · University Of California, San Francisco · R01 · FY2023 · AI

Natural History of HPV Infection to Neoplasia

$848,301
Anna-Barbara None Moscicki · University Of California Los Angeles · R37 · FY2014 · CA

Production of Non-Egg grown Influenza Vaccines

$848,254
Novavax, Inc. · UC1 · FY2000 · AI

Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions

$848,166
Christopher B Fox · Access To Advanced Health Institute · R01 · FY2020 · AI

Role of the microbiome in HIV vaccine induced heterogeneity

$848,148
James G. Kublin · Fred Hutchinson Cancer Research Center · R01 · FY2018 · AI

Antibody Based Therapeuticcs for Chikungunya Virus

$848,100
Michael S. Diamond · Washington University · R01 · FY2010 · AI

Task C12: Infectivity and Lethality of Filovirus strain(s) in NHP

$848,083
Alan D.t. Barrett · University Of Texas Med Br Galveston · N02 · FY2014 · AI